David Zawitz

CIK: 0002046750

Transaction Breakdown

Open Market Buys (P)2 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VRCA

Verrica Pharmaceuticals Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

VRCA
Verrica Pharmaceuticals Inc.
Aug 17, 2026
Purchase(P)
Direct
6K shares at avg. $4.98$30K
VRCA
Verrica Pharmaceuticals Inc.
Jun 5, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
171.3K shares-
VRCA
Verrica Pharmaceuticals Inc.
Nov 25, 2025
Purchase(P)
Direct
10K shares at avg. $4.24$42K
VRCA
Verrica Pharmaceuticals Inc.
Dec 9, 2024
Award(A)
Employee Stock Option (right to buy)
Direct
950K shares-

		Type	Shares	Price		Ownership
Aug 17, 2026	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	6,000	$4.98	$29,880	Direct
Jun 5, 2026	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	171,340	-	-	Direct
Nov 25, 2025	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	10,000	$4.24	$42,425	Direct
Dec 9, 2024	VRCA Verrica Pharmaceuticals Inc.	Award(A) Employee Stock Option (right to buy)	950,000	-	-	Direct

1-4 of 4 transactions

About Zawitz David

Zawitz David (SEC CIK 0002046750) files insider reports with the SEC as Chief Operating Officer of Verrica Pharmaceuticals Inc. (VRCA).

Signal8 holds 5 ownership filings by Zawitz David (1 Form 3, 4 Form 4), filed between Dec 9, 2024 and Aug 18, 2026. Those filings report 4 transactions, from Dec 9, 2024 to Aug 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zawitz David's filings is in WEST CHESTER, PA.

Recent filings by Zawitz David

Aug 17, 2026: Open-market purchase of VRCA shares (Form 4, code P).
Jun 5, 2026: Grant or award of VRCA derivative securities (Form 4, code A).
Nov 25, 2025: Open-market purchase of VRCA shares (Form 4, code P).
Dec 9, 2024: Grant or award of VRCA derivative securities (Form 4, code A).

Other insiders filing for Verrica Pharmaceuticals Inc. (VRCA)

Rieger Jayson, CEO and President
Rosenberg Noah L., CMO
Kirby John J., Interim CFO
Eichenfield Lawrence, Director
Nguyen Diem, Director
PRYGOCKI MARK A SR, Director

How to read Form 4 transaction codes